Organophosphate and Carbamate Poisoning - Pipeline Review, H1 2020

  • Life Sciences
  • 30 April 2020
  • 38 Pages
  • Formats:    
  • Report Code: 24WT-3600

Organophosphate Carbamate Poisoning Pipeline Review H1 - Overview


Summary

Latest Pharmaceutical and Healthcare disease pipeline guide Organophosphate and Carbamate Poisoning - Pipeline Review, H1 2020, provides an overview of the Organophosphate and Carbamate Poisoning (Other Diseases) pipeline landscape.

Organophosphates and carbamates are common insecticides that inhibit cholinesterase activity, causing acute muscarinic manifestations (salivation, lacrimation, urination, diarrhea, emesis, bronchorrhea, bronchospasm, bradycardia, miosis) and some nicotinic symptoms, including muscle fasciculations and weakness. Most patients have bradycardia and, if poisoning is severe, hypotension. CNS toxicity is common, sometimes with seizures and excitability and often with lethargy and coma. Pancreatitis is possible, and organophosphates may cause arrhythmias such as heart block and QTc interval prolongation.

Report Highlights

We are Pharmaceutical and Healthcare latest pipeline guide Organophosphate and Carbamate Poisoning - Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Organophosphate and Carbamate Poisoning (Other Diseases), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Organophosphate and Carbamate Poisoning (Other Diseases) pipeline guide also reviews of key players involved in therapeutic development for Organophosphate and Carbamate Poisoning and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Preclinical stages are 4 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 3 and 1 molecules, respectively.

Organophosphate and Carbamate Poisoning (Other Diseases) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from We are proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope
  • - The pipeline guide provides a snapshot of the global therapeutic landscape of Organophosphate and Carbamate Poisoning (Other Diseases).
  • - The pipeline guide reviews pipeline therapeutics for Organophosphate and Carbamate Poisoning (Other Diseases) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • - The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • - The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • - The pipeline guide reviews key companies involved in Organophosphate and Carbamate Poisoning (Other Diseases) therapeutics and enlists all their major and minor projects.
  • - The pipeline guide evaluates Organophosphate and Carbamate Poisoning (Other Diseases) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • - The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • - The pipeline guide reviews latest news related to pipeline therapeutics for Organophosphate and Carbamate Poisoning (Other Diseases)

Reasons to Buy
  • - Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • - Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • - Find and recognize significant and varied types of therapeutics under development for Organophosphate and Carbamate Poisoning (Other Diseases).
  • - Classify potential new clients or partners in the target demographic.
  • - Develop tactical initiatives by understanding the focus areas of leading companies.
  • - Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • - Formulate corrective measures for pipeline projects by understanding Organophosphate and Carbamate Poisoning (Other Diseases) pipeline depth and focus of Indication therapeutics.
  • - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • - Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Organophosphate and Carbamate Poisoning - Overview
Organophosphate and Carbamate Poisoning - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Organophosphate and Carbamate Poisoning - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Organophosphate and Carbamate Poisoning - Companies Involved in Therapeutics Development
AntoXa Corp
Countervail Corp
PlantVax Inc
Organophosphate and Carbamate Poisoning - Drug Profiles
AM-132 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
galantamine hydrobromide - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PlantVax-1502-HN - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Recombinant Butyrylcholinesterase for Carbamate and Organophosphate Poisoning - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
RS-194B - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule for Organophosphate Poisoning - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Activate Acetylcholinesterase for Organophosphate Poisoning - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Agonize GABAA for Nerve Gas and Organophosphate Poisoning - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Organophosphate and Carbamate Poisoning - Dormant Projects
Organophosphate and Carbamate Poisoning - Discontinued Products
Organophosphate and Carbamate Poisoning - Product Development Milestones
Featured News & Press Releases
Feb 21, 2016: Israeli parent patent for the use of Galantamine and Antimuscarinic Agent For Organophosphorus Poisoning awarded
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables

Number of Products under Development for Organophosphate and Carbamate Poisoning, H1 2020

Number of Products under Development by Companies, H1 2020

Number of Products under Development by Universities/Institutes, H1 2020

Products under Development by Companies, H1 2020

Products under Development by Universities/Institutes, H1 2020

Number of Products by Stage and Target, H1 2020

Number of Products by Stage and Mechanism of Action, H1 2020

Number of Products by Stage and Route of Administration, H1 2020

Number of Products by Stage and Molecule Type, H1 2020

Organophosphate and Carbamate Poisoning - Pipeline by AntoXa Corp, H1 2020

Organophosphate and Carbamate Poisoning - Pipeline by Countervail Corp, H1 2020

Organophosphate and Carbamate Poisoning - Pipeline by PlantVax Inc, H1 2020

Organophosphate and Carbamate Poisoning - Dormant Projects, H1 2020

Organophosphate and Carbamate Poisoning - Discontinued Products, H1 2020List of Figures

Number of Products under Development for Organophosphate and Carbamate Poisoning, H1 2020

Number of Products under Development by Universities/Institutes, H1 2020

Number of Products by Top 10 Targets, H1 2020

Number of Products by Stage and Top 10 Targets, H1 2020

Number of Products by Top 10 Mechanism of Actions, H1 2020

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2020

Number of Products by Top 10 Routes of Administration, H1 2020

Number of Products by Stage and Top 10 Routes of Administration, H1 2020

Number of Products by Top 10 Molecule Types, H1 2020

Number of Products by Stage and Top 10 Molecule Types, H1 2020
CHOOSE YOUR BUYING OPTION

NEED A HELP?

Submit your research need or query below

+91 9169162030 (Asia)
help@primemarketreports.com